Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non-small-cell Lung Cancer

Clin Lung Cancer. 2019 Sep;20(5):e555-e559. doi: 10.1016/j.cllc.2019.06.021. Epub 2019 Jun 26.

¹ First Department of Medicine, Hokkaido University Hospital, Sapporo, Japan. Electronic address: konishj@med.hokudai.ac.jp.
² First Department of Medicine, Hokkaido University Hospital, Sapporo, Japan.
³ First Department of Medicine, Hokkaido University Hospital, Sapporo, Japan; Department of Respiratory Medicine, Oji General Hospital, Tomakomai, Japan.
⁴ Research Division of Genome Companion Diagnostics, Hokkaido University Hospital, Sapporo, Japan.
⁵ Respiratory Center, Asahikawa Medical University, Asahikawa, Japan.
⁶ Center for Advanced Research and Education, Asahikawa Medical University, Asahikawa, Japan.
⁷ Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.
⁸ Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

No abstract available

Keywords: ALK-TKI; MET; Mutation; NGS; Sequential treatment.

Publication types